Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $70.55 | Total: $352.75 |
| 1 | 10 | $59.76 | Total: $597.60 |
| 1 | 25 | $50.63 | Total: $1,265.75 |
| 1 | 50 | $43.16 | Total: $2,158.00 |
| 1 | 100 | $37.35 | Total: $3,735.00 |
Overview
PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 2.8 ?M against PHGDH, and it can be used in cancer research.
Chemical Properties
| Molecular Formula | C24H18FN3O4S2 |
| Molecular Weight | 495.55 |
| CAS Numbers | 2893778-31-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | N(C(=O)C1=CC=C(S(NC2=CC(C(C)=O)=CC=C2)(=O)=O)C=C1)C3=NC(=CS3)C4=CC(F)=CC=C4 |
Storage and Handling
0C Short Term, -20C Long Term
References
Gao D, et al. Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy. J Med Chem. 2023;66[1] 285-305.